SRPT Deadline: SRPT Investors with Losses in Excess of $100K Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sarepta Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Sarepta Therapeutics securities between June 22, 2023, and June 24, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [3][5]. - The lawsuit alleges that Sarepta made false and misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, which is intended for patients with Duchenne muscular dystrophy [5]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant settlements for investors [4]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and recovering over $438 million for investors in 2019 [4].